Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels

OBJECTIVE: The liver-derived circulating PCSK9 enhances the degradation of the LDL receptor (LDLR) in endosomes/lysosomes. PCSK9 inhibition or silencing is presently used in clinics worldwide to reduce LDL-cholesterol, resulting in lower incidence of cardiovascular disease and possibly cancer/metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Fruchart Gaillard, Carole, Ouadda, Ali Ben Djoudi, Ciccone, Lidia, Girard, Emmanuelle, Mikaeeli, Sepideh, Evagelidis, Alexandra, Le Dévéhat, Maïlys, Susan-Resiga, Delia, Lajeunesse, Evelyne Cassar, Nozach, Hervé, Ramos, Oscar Henrique Pereira, Thureau, Aurélien, Legrand, Pierre, Prat, Annik, Dive, Vincent, Seidah, Nabil G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816786/
https://www.ncbi.nlm.nih.gov/pubmed/36566984
http://dx.doi.org/10.1016/j.molmet.2022.101662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816786/
https://www.ncbi.nlm.nih.gov/pubmed/36566984
http://dx.doi.org/10.1016/j.molmet.2022.101662

Ejemplares similares